Previous 10 | Next 10 |
Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced registered direct offering with a single healthcare-focused U.S. institutional investor for the purchase of 48,000,000 shares of the Company’s common stock (or common stock equivalents in lieu t...
Athersys ( NASDAQ: ATHX ) shares gained 2% pre-market on Monday after the biotechnology firm announced a $12M securities offering . The company entered into a definitive agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of...
Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 48,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof) an...
Shares of micro-cap biotech Athersys ( NASDAQ: ATHX ) lost 8.8% to $0.26 in Friday late afternoon trading, after the company reported a quarterly loss that was in-line with estimates and a fall in cash and cash equivalents. ATHX after hours on Thursday posted Q2 GA...
Athersys, Inc. (ATHX) Q2 2022 Earnings Conference Call August 11, 2022 16:30 ET Company Participants Cindy Jacobs - President, Chief Medical Officer & Director Jerry Wan - Principal Accounting Officer Daniel Camardo - Chief Executive Officer Conference ...
Image source: The Motley Fool. Athersys (NASDAQ: ATHX) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Athersys (ATHX) Q2 2022 Earnings Call Transcript
Athersys press release ( NASDAQ: ATHX ): Q2 GAAP EPS of -$0.09 in-line. Revenue of $2.32M. At June 30, 2022, the company had $13.4M in cash and cash equivalents, compared to $37.4M at December 31, 2021. For further details see: Athersys GAAP EPS of -$0.09 in-...
Corporate restructuring underway and MASTERS-2 clinical trial prioritized Conference call begins at 4:30 p.m. Eastern time today Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a busine...
Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, ...
Kasey Rosado has been named interim CFO of regenerative medicine company Athersys ( NASDAQ: ATHX ). The appointment comes as the firm announced engagement with Ankura Consulting Group. As Senior Managing Director at Ankura, Ms. Rosado provides advisory support for doze...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...